Clouds loom for Novartis’s MorphoSys buy
Pelabresib is delayed, and Novartis writes off $800m of the €2.7bn purchase.
Pelabresib is delayed, and Novartis writes off $800m of the €2.7bn purchase.
The focus for divarasib in second-line lung is now the head-to-head Krascendo-1 trial.
Meanwhile, Tecvayli stalls, but J&J still hopes for growth.
Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.